ACORI RESEARCH REVIEW: OCTOBER 2026


ACORI DCT Roundtable Series

Making clinical trials more inclusive, efficient, and patient-centered is key to improving patient outcomes. It ensures patients can get the treatments they need regardless of logistical barriers such as distance and travel limitations. The advent of decentralized clinical trials (DCTs) greatly expanded the reach of therapy, but implementation challenges have hampered their broad uptake in the community.


ACORI Clinical Workforce Collaboration to Build an APP Roadmap to PI Competence

The number of oncology advanced practice providers (APPs) has increased substantially over the last decade. During that time, APPs have increasingly playeda significant role in clinical trials, yet gaps in education, role clarity, and policies limit full engagement in research. Highlighted by the fact that more than 90% of clinical trials are supported by APPs but fewer than 5% serve as principal investigators, ACCC and partners set out to develop a national initiative to identify needs and create resources to support full APP engagement in clinical research.


Highlands Oncology Opens Expanded Clinical Trials Suite

Accessing clinical trials in rural communities can be cumbersome. Participation in studies may require specialized labs, specific diagnostic imaging, and specialty drugs, all of which may be spread over multiple locations. This can lead patients to optout of care because of the heavy logistical burden.


Advancing Equity in Cancer Clinical Trials Through Pharmacist Led Education

Clinical trial access is a common challenge for patients in rural areas across the United States, but Hawaii’s geography poses unique barriers. The University of Hawai’i Cancer Center, located on the island of Oahu, is the state’s only National Cancer Institute-designated Comprehensive Cancer Center and the only site for most oncology clinical trials in Hawaii. Oncology programs on the other islands are typically rural, independently operated, rather than part of an integrated health system, and vary widely in staff and resource availability. While some of these programs have begun or expanded research programs in recent years, most patients in these settings still must fly from their island to Oahu to participate in clinical trials.


The Clinical Trial Modernization Act

The field of clinical research facesa persistent challenge in recruiting diverse and representative study populations. Word of thisissue has reached federal lawmakers, who are drafting legislation to enable and expand access to clinical trials. The Clinical Trial Modernization Act aims to reduce barriers to patient participation, with special emphasis on groups that are commonly underrepresented in research. This legislation was first introduced in the House of Representatives last year by Raul Ruiz (D-California) and August Pfluger (R-Texas), and its companion bill was introduced in the Senate this spring by Tim Scott (R-South Carolina) and Mark Warner (D-Virginia). With bipartisan engagement in both chambers and support from major advocacy organizations, including the American Cancer Society Cancer Action Network (ACS CAN), this bill is a promising step toward impactful policy change.


ShareForCures Expands Opportunities for Community Patients to Contribute to Breast Cancer Research

The Hematology Oncology Pharmacy Association (HOPA) has launched Time to Talk: Clinical Trials, an initiative aimed at addressing a long-standing challenge in oncology: Clinical trial participation often does not reflect the diversity of the patients most affected by cancer.


ONE in a MILLION Campaign Mobilizes Communities Around Bresat Cancer Clinical Trials

Clinical trials are essential to developing safer, more effective approaches to preventing, diagnosing, and treating breast cancer. Yet many people affected by breast cancer never learn about clinical trials as a potential care option—or encounter financial, logistical, geographic, and systemic barriers that make participation difficult.